ID   JCA-1
AC   CVCL_4015
SY   JCA1
DR   BioSample; SAMN03151947
DR   cancercelllines; CVCL_4015
DR   Wikidata; Q54898538
RX   CelloPub=CLPUB00698;
RX   PubMed=2195744;
RX   PubMed=11304728;
RX   PubMed=11522622;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a T24 derivative (PubMed=11304728; PubMed=11522622; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from a 67 year old male patient with prostate carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00216.
CC   Population: Caucasian; Swedish.
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (PubMed=11304728; PubMed=11522622).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (PubMed=11304728; PubMed=11522622).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): PubMed=11304728; PubMed=11522622
ST   Amelogenin: X
ST   D13S317: 12
ST   D18S51: 16,18
ST   D21S11: 29
ST   D3S1358: 16
ST   D5S818: 10,12
ST   D7S820: 10,11
ST   D8S1179: 14
ST   FGA: 22
ST   vWA: 17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0554 ! T24
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 26
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands.
//
RX   PubMed=2195744; DOI=10.1016/0090-4295(90)80319-I;
RA   Muraki J., Addonizio J.C., Choudhury M.S., Fischer J., Eshghi M.,
RA   Davidian M.M., Shapiro L.R., Wilmot P.L., Nagamatsu G.R., Chiao J.W.;
RT   "Establishment of new human prostatic cancer cell line (JCA-1).";
RL   Urology 36:79-84(1990).
//
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.;
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
//
RX   PubMed=11522622;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Miller G.J.;
RT   "TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma
RT   cells and are not of prostatic origin.";
RL   Cancer Res. 61:6340-6344(2001).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//